Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant Intratumoral Ipilimumab + Nivolumab in Localized Melanoma
NCT07230613Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in melanoma, sponsored by Unicancer. Started Jan 2026; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07230613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230613.